CaMKII Serine 280 O-GlcNAcylation Links Diabetic Hyperglycemia to Proarrhythmia
暂无分享,去创建一个
C. Ripplinger | D. Bers | B. Hegyi | Christopher Y. Ko | Jeffrey R. Erickson | Anna Fasoli | Julie Bossuyt | Srinivas Tapa | Marisa M Ciccozzi | Erin Y. Shen | Benjamin W Van | Chidera C Alim | Jeffrey R Erickson
[1] Mark E. Anderson,et al. Loss of CASK Accelerates Heart Failure Development , 2021, Circulation research.
[2] D. Bers,et al. Two-hit mechanism of cardiac arrhythmias in diabetic hyperglycemia: reduced repolarization reserve, neurohormonal stimulation and heart failure exacerbate susceptibility. , 2021, Cardiovascular research.
[3] Manuel F. Navedo,et al. Hyperglycemia regulates cardiac K+ channels via O-GlcNAc-CaMKII and NOX2-ROS-PKC pathways , 2020, Basic Research in Cardiology.
[4] R. Cole,et al. Oxidized-CaMKII and O-GlcNAcylation cause increased atrial fibrillation in diabetic mice by distinct mechanisms. , 2020, The Journal of clinical investigation.
[5] D. Bers,et al. Hyperglycemia Acutely Increases Cytosolic Reactive Oxygen Species via O-linked GlcNAcylation and CaMKII Activation in Mouse Ventricular Myocytes , 2020, Circulation research.
[6] G. Filippatos,et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.
[7] F. Cosentino,et al. The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.
[8] A. Leite-Moreira,et al. O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart from Failure. , 2019, Circulation.
[9] W. Dillmann. Diabetic Cardiomyopathy: What Is It and Can It Be Fixed? , 2019, Circulation research.
[10] D. Bers,et al. Enhanced Depolarization Drive in Failing Rabbit Ventricular Myocytes: Calcium-Dependent and &bgr;-Adrenergic Effects on Late Sodium, L-Type Calcium, and Sodium-Calcium Exchange Currents , 2019, Circulation. Arrhythmia and electrophysiology.
[11] C. Yancy,et al. Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.
[12] D. Bers,et al. Diabetic Hyperglycemia Regulates Potassium Channels and Arrhythmias in the Heart via Autonomous CaMKII Activation by O-Linked Glycosylation , 2019, Biophysical Journal.
[13] D. Bers,et al. CaMKII signaling in heart diseases: Emerging role in diabetic cardiomyopathy. , 2019, Journal of molecular and cellular cardiology.
[14] D. Bers,et al. Cardiac CaMKII activation promotes rapid translocation to its extra-dyadic targets. , 2018, Journal of molecular and cellular cardiology.
[15] Ye Chen-Izu,et al. β-adrenergic regulation of late Na+ current during cardiac action potential is mediated by both PKA and CaMKII. , 2018, Journal of molecular and cellular cardiology.
[16] L. Maier,et al. Empagliflozin reduces Ca/calmodulin‐dependent kinase II activity in isolated ventricular cardiomyocytes , 2018, ESC heart failure.
[17] Zhong Jian,et al. Complex electrophysiological remodeling in postinfarction ischemic heart failure , 2018, Proceedings of the National Academy of Sciences.
[18] J. Sowers,et al. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity , 2018, Circulation research.
[19] D. Bers,et al. Altered Repolarization Reserve in Failing Rabbit Ventricular Myocytes: Calcium and &bgr;-Adrenergic Effects on Delayed- and Inward-Rectifier Potassium Currents , 2018, Circulation. Arrhythmia and electrophysiology.
[20] E. Furlong,et al. A proteolytic fragment of histone deacetylase 4 protects the heart from failure by regulating the hexosamine biosynthetic pathway , 2017, Nature Medicine.
[21] Akshay S. Desai,et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. , 2017, The lancet. Diabetes & endocrinology.
[22] F. Charpentier,et al. The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model , 2017, Diabetes.
[23] D. Bers,et al. CaMKII-dependent phosphorylation of RyR2 promotes targetable pathological RyR2 conformational shift. , 2016, Journal of molecular and cellular cardiology.
[24] M. Fischereder,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.
[25] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[26] R. Nishimura,et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study , 2015, Cardiovascular Diabetology.
[27] A. Leite-Moreira,et al. Diastolic dysfunction in the diabetic continuum: association with insulin resistance, metabolic syndrome and type 2 diabetes , 2015, Cardiovascular Diabetology.
[28] D. Vocadlo,et al. The Emerging Link between O-GlcNAc and Alzheimer Disease* , 2014, The Journal of Biological Chemistry.
[29] R. Ritchie,et al. Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways. , 2014, Pharmacology & therapeutics.
[30] Junfeng Ma,et al. O-GlcNAc profiling: from proteins to proteomes , 2014, Clinical Proteomics.
[31] Mark E. Anderson,et al. Mechanisms of Altered Ca2+ Handling in Heart Failure , 2013, Circulation research.
[32] Gerald W. Hart,et al. Diabetic Hyperglycemia activates CaMKII and Arrhythmias by O linked Glycosylation , 2013, Nature.
[33] D. Bers,et al. While systolic cardiomyocyte function is preserved, diastolic myocyte function and recovery from acidosis are impaired in CaMKIIδ-KO mice. , 2013, Journal of molecular and cellular cardiology.
[34] I. Efimov,et al. Diabetes increases mortality after myocardial infarction by oxidizing CaMKII. , 2013, The Journal of clinical investigation.
[35] W. Linke,et al. Crucial Role for Ca2+/Calmodulin-Dependent Protein Kinase-II in Regulating Diastolic Stress of Normal and Failing Hearts via Titin Phosphorylation , 2013, Circulation research.
[36] T. Saikawa,et al. Activation of CaMKII as a key regulator of reactive oxygen species production in diabetic rat heart. , 2012, Journal of molecular and cellular cardiology.
[37] Matthew S Macauley,et al. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. , 2012, Nature chemical biology.
[38] D. Bers,et al. Location Matters: Clarifying the Concept of Nuclear and Cytosolic CaMKII Subtypes , 2011, Circulation research.
[39] Mark E. Anderson,et al. Oxidation of CaMKII determines the cardiotoxic effects of aldosterone , 2011, Nature Medicine.
[40] Donald M Bers,et al. CaMKII in myocardial hypertrophy and heart failure. , 2011, Journal of molecular and cellular cardiology.
[41] D. Bers,et al. Fluorescence Resonance Energy Transfer–Based Sensor Camui Provides New Insight Into Mechanisms of Calcium/Calmodulin-Dependent Protein Kinase II Activation in Intact Cardiomyocytes , 2011, Circulation research.
[42] F. Gueyffier,et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials , 2011, BMJ : British Medical Journal.
[43] G. Hart,et al. Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. , 2011, Annual review of biochemistry.
[44] Ferdinando Giacco,et al. Oxidative stress and diabetic complications. , 2010, Circulation research.
[45] Keiichiro Suzuki,et al. Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy. , 2010, Glycobiology.
[46] Steven P Jones,et al. O-linked β-N-acetylglucosamine transferase is indispensable in the failing heart , 2010, Proceedings of the National Academy of Sciences.
[47] C. Alpers,et al. Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.
[48] Tong Zhang,et al. Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. , 2009, The Journal of clinical investigation.
[49] Hugo A. Katus,et al. The δ isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload , 2009, Proceedings of the National Academy of Sciences.
[50] Steven P Jones,et al. Unique Hexosaminidase Reduces Metabolic Survival Signal and Sensitizes Cardiac Myocytes to Hypoxia/Reoxygenation Injury , 2008, Circulation research.
[51] Mark E. Anderson,et al. A Dynamic Pathway for Calcium-Independent Activation of CaMKII by Methionine Oxidation , 2008, Cell.
[52] D. Bers. Calcium cycling and signaling in cardiac myocytes. , 2008, Annual review of physiology.
[53] Gerald W. Hart,et al. Cycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins , 2007, Nature.
[54] D. Bers,et al. Ca2+/Calmodulin–Dependent Protein Kinase Modulates Cardiac Ryanodine Receptor Phosphorylation and Sarcoplasmic Reticulum Ca2+ Leak in Heart Failure , 2005, Circulation research.
[55] T. Rea,et al. Diabetes, glucose level, and risk of sudden cardiac death. , 2005, European heart journal.
[56] G. Lip,et al. Diabetes mellitus, the renin-angiotensin-aldosterone system, and the heart. , 2004, Archives of internal medicine.
[57] Andy Hudmon,et al. Structure-function of the multifunctional Ca2+/calmodulin-dependent protein kinase II. , 2002, The Biochemical journal.
[58] D. Bers. Cardiac excitation–contraction coupling , 2002, Nature.
[59] G. Tomaselli,et al. Electrophysiological remodeling in hypertrophy and heart failure. , 1999, Cardiovascular research.
[60] C. Carlson,et al. Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure. , 2012, Physiological genomics.
[61] A. Ceriello. Postprandial hyperglycemia and diabetes complications: is it time to treat? , 2005, Diabetes.
[62] Kumar Sharma,et al. Mouse models of diabetic nephropathy. , 2005, Journal of the American Society of Nephrology : JASN.